Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 7, Issue 2, 1996, Pages 183-190

  Cohen, Margo P ^a,b   Ziyadeh, Fuad N ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Exocell Inc   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Albumin; Glomerulus; Glycation; Hyperglycemia; Mesangium

Indexed keywords

ALBUMIN; AMADORI REARRANGEMENT COMPOUND; MONOCLONAL ANTIBODY; PLASMA PROTEIN; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; GLYCATION; HUMAN; HYPERGLYCEMIA; MESANGIUM CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0029932798     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Freidman EA: Diabetic nephropathy: Strategies in prevention and management. Kidney Int 1982;21:720-738.
2. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360.
3. Noth RH: Diabetic nephropathy: Hemodynamic basis and implications for disease management. Ann Intern Med 1989;110:795-813.
4. Krowelski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history of nephropathy in Type I diabetes. Am J Med 1985;78:785-794.
5. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in Type I (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983;25:496-501.
6. Ireland JT, Patnik B, Duncan LL: Glomerular ultrastructure in secondary diabetes and normal subjects. Diabetes 1967;16:628-635.
7. Gibbs GE, Wilson RB, Gifford H: Glomerulosclerosis, in the long-term alloxan diabetic monkey. Diabetes 1966; 15:258-261.
8. Orskov HT, Olsen ST, Nielson K, Rafaelson OJ, Lundbaek K: Kidney lesions in rats with severe long-term alloxan diabetes. Diabetologia 1965;1:172-179.
9. Bloodworth JM, Engerman RL, Powers KL: Experimental diabetic microangiopathy. Basement membrane studies in the dog. Diabetes 1969;18:455-458.
10. Hagg E: Glomerular basement membrane thickening in rats with long-term alloxan diabetes. Acta Pathol Microbiol Scand 1974;A82:211-219.
11. Steffes MW, Buchwald H, Wigness BD, et al.: Diabetic nephropathy in the uninephrectomized dog. Microscopic lesions after one year. Kidney Int 1982;21:721-724.
12. Fox CJ, Darby SC, Ireland JT, Sonksen PH: Blood glucose control and glomerular capillary basement membrane thickening in experimental diabetes. Br Med J 1977;2:605-607.
13. Jones CW, West MS, Hong DT, Jonasson O: Peripheral glomerular basement membrane thickness in the normal and diabetic monkey. Lab Invest 1984;51:193-198.
14. Cohen MP, Dasmahapatra A, Wu VY: Deposition of basement membrane in vitro by normal and diabetic rat renal glomeruli. Nephron 1981;257:146-151.
15. Grant ME, Harwood R, Williams IF: Increased synthesis of glomerular basement membrane collagen in streptozotocin diabetes. J Physiol 1976;257:56-57.
16. Khalifa A, Cohen MP: Glomerular protocollagen lysyl hydroxylase activity in streptozotocin diabetes. Biochim Biophys Acta 1975;386:332-339.
17. Ristelli J, Koivisto VA, Akerblom HK, Kivirikko KI: Intracellular enzymes of collagen biosynthesis in rat kidney with strepotozotocin diabetes. Diabetes 1976; 25:1066-1070.
18. Spiro RG, Spiro MJ: Tissue and subcellular distribution of glycosyltransferases and the effect of various conditions on enzyme levels. J Biol Chem 1971;246: 4919-4925.
19. Cohen MP, Khalifa A: Renal glomerular collagen synthesis in streptozotocin diabetes. Reversal of increased basement membrane synthesis with insulin therapy. Biochim Biophys Acta 1977;500:395-404.
20. Hasslacher C, Wahl P: Influence of diabetes control on synthesis of protein and basement membrane collagen in isolated glomeruli of diabetic rats. Res Exp Med 1980;176:247-253.
21. Cohen MP, Khalifa A: Effect of diabetes and insulin on renal glomerular protocollagen hydroxylase activities. Biochim Biophys Acta 1977;496:88-94.
22. Spiro G, Spiro MJ: Effect of diabetes on the biosynthesis of renal glomerular basement membrane. Studies on the glucosyltransferase. Diabetes 1971;20:641-648.
23. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
24. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: A clinical trial of angiotensin converting enzyme inhibitor in the nephropathy of insulin-dependent diabetes. N Engl J Med 1993;329:1456-1463.
25. Winegrad AI: Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987;36: 396-406.
26. Green DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositide and the sodium potassium ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599-606.
27. Green DA, Lattimer SA, Sima AAF: Are disturbances of sorbitol, phosphoinositide, and Na/K-ATPase regulation involved in the pathogenesis of diabetic neuropathy? Diabetes 1988;37:688-693.
28. Yorek MA, Stefani MR, Moore SA: Acute and chronic exposure of mouse cerebral microvessel endothelial cells to increased concentrations of glucose and galactose: Effect on myo-inositol metabolism, PGE2 synthesis, and Na/K-ATPase transport activity. Metabolism 1991;40:347-358.
29. Cohen MP, Dasmahapatra A, Shapiro E: Decreased rat glomerular sodium potassium adenosine triphosphatase activity in acute streptozotocin diabetes and its prevention by oral sorbinil. Diabetes 1985;34:1071-1074.
30. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from strepotozotocin diabetic rats. Possible mediation by glucose. J Clin Invest 1989;83: 1667-1675.
31. Cohen MP, Ku L: Inhibition of fibronectin binding to matrix components by nonenzymatic glycosylation. Diabetes 1984;33:970-974.
32. Lien YH, Stern R, Fu JC, Seigel RC: Inhibition of collagen fibril formation in vitro and subsequent cross-linking by glucose. Science 1984;225:1489-1491.
33. Guitton JD, LePape A, Sizaret PY, Muh JP: Effect of in vitro nonenzymatic glucosylation of Type I collagen fibrillogenesis. Biosci Rep 1981;1:945-954.
34. Guitton JD, LePape A, Muh JP: Influence of in vitro nonenzymatic glucosylation on physicochemical parameters of type I collagen. Collagen Rel Res 1984;4: 253-264.
35. Tarsio JF, Wigness B, Rhode RD, Rupp W, Buchwald H, Furcht T: Nonenzymatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus. Diabetes 1985;43:477-484.
36. Monnier VM, Stevens VJ, Cerami A: Nonenzymatic glycosylation, sulfhydryl oxidation, and aggregation of lens proteins in experimental sugar cataracts. J Exp Med 1979;150:1098-1107.
37. Witztum JL Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D: Nonenzymatic glucosylation of low density lipoprotein alters its biologic activity. Diabetes 1982;31:283-291.
38. Steinbrecher UP, Witztum JL: Glycosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33:130-134.
39. Brownlee M, Cerami A, Vlassara H: Advanced glycation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
40. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes induced arterial wall protein cross-linking. Science 1986;232:1629-1632.
41. Vlassara H, Brownlee M, Manogue K, Dinarello C, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodelling. Science 1988;240:1546-1548.
42. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H: Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010-9014.
43. Makita ZH, Radoff S, Rayfield EJ, et al.: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
44. Oates PJ: Diabetic nephropathy, renal hemodynamics and aldose reductase inhibitors. Drug Dev Res 1994; 32:104-116.
45. Tomlinson DR: Aldose reductase inhibitors and the complications of diabetes mellitus. Diabetic Med 1993; 10:214-230.
46. Sarges R, Oates PJ: Aldose reductase inhibitors: Recent developments. Prog Drug Res 1993;40:99-161.
47. Monnier VM, Sell DR, Miyata S, Ramanakoppa HN, Odetti P, Lapolla A: Advanced Maillard reaction products as markers for tissue damage in diabetes and uraemia: Relevance to diabetic nephropathy. Acta Diabetol 1992;29:130-135.
48. Monnier VM: Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 1990;45: B105-B111.
49. Vlassara H: Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994;124:19-30.
50. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM: The biosynthesis of human hemoglobin AlC: Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976;57: 1652-1659.
51. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science 1978;200:21-27.
52. Higgins PJ, Bunn HF: Kinetic analysis of nonenyzmatic glycosylation of hemoglobin. J Biol Chem 1981;256: 5204-5208.
53. Koenig RJ, Blobstein SH, Cerami A: Structure of carbohydrate and hemoglobin A. J Biol Chem 1982;252: 2992-2997.
54. Cohen MP. Diabetes and Protein Glycosylation: Measurement and Biologic Relevance. New York: Springer Verlag; 1986.
55. Day JF, Ingelbretsen CG, Ingelbretsen WR, Baynes J, Thorpe SR: Nonenzymatic glucosylation of serum proteins and hemoglobin: Response to changes in blood glucose levels in diabetic rats. Diabetes 1980;29:524-527.
56. Day JF, Thorpe JR, Baynes JM: Nonenzymatically glucosylated albumin: In vitro preparation and isolation from normal human serum. J Biol Chem 1979;254: 595-597.
57. Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes J: Enhanced nonenzymatic glucosylation of serum albumin in diabetes mellitus. Proc Natl Acad Sci USA 1979; 76:4258-4261.
58. Koenig R, Ceraini A: Hemoglobin AlC and diabetes mellitus. Annu Rev Med 1980;31:29-39.
59. Cohen MP, Hud E: Measurement of plasma glycoalbumin levels with a monoclonal antibody-based ELISA. J Immunol Methods 1989;122:279-283.
60. Hud E, Cohen MP: Evaluation and performance characteristics of a novel monoclonal antibody based ELISA for glycated albumin. Clin Chim Acta 1989;154:157-164.
61. Cohen MP, Urdanivia E, Surma ML, Wu VY: Increased glycosylation of glomerular basement membrane collagen in diabetes. Biochem Biophys Res Commun 1980; 5:765-769.
62. Cohen MP, Wu VY: Identification of specific amino acids in diabetic glomerular basement membrane collagen subject to nonenzymatic glycosylation in vivo. Biochem Biophys Res Commun 1981;100:1549-1554.
63. Vogt BW, Schleicher E, Wieland OH: ∈-amino-lysine bound glucose in human tissues obtained at autopsy: Increase in diabetes mellitus. Diabetes 1983;31:1123-1127.
64. Perejda A, Uitto J: Nonenzymatic glycosylation of collagen and other proteins: Relationship to development of complications. Collagen Rel Res 1982;2:81-88.
65. Schleicher E, Wieland OH: Changes of human glomerular basement membrane in diabetes mellitus. J Clin Chem Clin Biochem 1984;22:223-227.
66. Trueb B, Fluckiger R, Winterhalter KH: Nonenzymatic glycosylation of basement membrane collagen in diabetes mellitus. Collagen Rel Res 1984;4:239-251.
67. Uitto J, Perejda AJ, Grant GA, Rowold EA, Kilo C, Williamson JR: Glycosylation of human glomerular basement membrane collagen: Increased content of hexose in the ketoamine linkage and unaltered hydroxylysine glycosides in patients with diabetes. Connect Tissue Res 1982;10:287-296.
68. McCance DR, Dyer DG, Dunn JA, et al.: Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus. J Clin Invest 1993;91:2470-2478.
69. Williams SK, Devenny JJ, Bitensky MW: Micropinocytic ingestion of glycosylated albumin by isolated microvessels: Possible role in the pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci USA 1991;78: 2393-2397.
70. Williams SK, Siegal RK: Preferential transport of nonenzymatically glycosylated ferritin across the kidney glomerulus. Kidney Int 1985;28:146-152.
71. Daniels BS, Hauser BE: Glycation of albumin, not glomerular basement membrane, alters permeability in an in vitro model. Diabetes 1992;41:1415-1421.
72. 2 [Abstract]. Clin Res 1992;40:179A.
73. 2 production in diabetes: Role of glycated proteins [Abstract]. J Am Soc Nephrol 1993;4:791A.
74. McVerry BA, Hopp A Fisher C, Huehns RR: Production of pseudodiabetic renal glomerular changes in mice after repeated injection of glycosylated proteins. Lancet 1980;2:738-740.
75. Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE: Early glycosilation products induce glomerular hyperfiltration in normal rat. Kidney Int 1992;42:875-881.
76. Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989;38:1077-1081.
77. Saito Y, Kida H, Takeda SI, et al.: Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions. Kidney Int 1988;34:389-396.
78. Steffes MW, Bilous W, Sutherland DER, Mauer SM: Cell and matrix components of the glomerular mesangium in Type I diabetes. Diabetes 1992;41:679-684.
79. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC: Structural functional relationship in diabetic nephropathy. J Clin Invest 1984;74: 1143-1155.
80. Osterby R, Parving H-H, Hommel E, Jorgensen HE, Lokkegard H: Glomerular structure and function in diabetic nephropathy: Early to advanced stages. Diabetes 1990;398:1057-1063.
81. Abrass CK, Peterson CV, Raugi GS: Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats. Diabetes 1988;37:1695-1702.
82. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose- induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 1992;42:647-656.
83. Ayo SH, Radnik GA, Garoni JA, Glass WF, Kreisberg JI: High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 1990;136:1339-1348.
84. Ayo SH, Radnik GA, Glass WF, et al.: Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high glucose. Am J Physiol 1991;260:F185-F191.
85. Crowley ST, Brownlee M, Edelstein D, et al.: Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells. Diabetes 1991;40:540-547.
86. Silbiger S, Crowley S, Shan Z, Brownlee M, Satriano J, Schlondorff DD: Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int 1993;43:853-864.
87. Haneda M, Kikkawa R, Horide N, et al.: Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells. Diabetologia 1991;34:198-200.
88. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker L: Receptor specific Increase in extracellular matrix proteins in cultured mesangial cells by advanced glycosylation end products. Proc Natl Acad Sci USA 1992;89:2873-2377.
89. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin rats. Possible mediation by glucose. J Clin Invest 1989;83:1667-1675.
90. Ayo SH, Radnik RA, Garoni J, Troyer DA, Kreisberg JI: High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991;261:F571-F577.
91. Kreisberg JI, Radnik RA, Ayo SH, Garoni JA, Saikumar P: High glucose elevates cfos and cjun transcripts and proteins in mesangial cell cultures. Kidney Int 1994;46: 105-112.
92. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994;93:536-542.
93. Cohen MP, Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int 1994;45:475-484.
94. Cohen MP, Hud E: Production and characterization of monoclonal antibodies against human glycoalbumin. J Immunol Meth 1989;117:121-129.
95. Ziyadeh FN, Simmons DA, Snipes ER, Goldfarb S: Effects of myo-inositol on cell proliferation and collagen transcription and secretion in proximal tubule cells cultured in elevated glucose. J Am Soc Nephrol 1991; 1:1220-1229.
96. Ziyadeh FN, Snipes ET, Watanabe M, Alvarez R, Goldfarb S, Haverty TP: High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am J Physiol 1990;259:704-714.
97. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 1992;41:107-114.
98. Lane PH, Steffes MW, Fioretto P, Mauer SM: Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993;43:661-667.
99. Ziyadeh FN: Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int 1993; 43:114-120.
100. Ziyadeh FN: The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993;22:736-744.
101. Ziyadeh FN, Cohen MP: Effects of glycated albumin on mesangial cells: Evidence for a role in diabetic nephropathy. Mol Cell Biochem 1993;125:19-25.
102. Nakamura T, Fukui M, Ebihara I, et al.: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993;42:450-456.
103. Yamamoto T, Nakamura T, Noble N, Rouslahti E, Border WA: Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
104. Fukui M, Nakamura T, Ebihara L Shirato I, Tomino Y, Koide H: ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 1992;41:1520-1527.
105. Sharma K, Ziyadeh FN: Renal hypertrophy is associated with upregulation of TGF-β1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994; 267:F1094-F1101.
106. Yang C-W, Hattori M, Vlassara H, et al.: Overexpression of transforming growth factor-β1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 1995;5:1610-1617.
107. Pankewycz OG, Guan J-X, Bolton WK, Gomez A, Benedict JF: Renal TGF-β regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int 1994;46:748-758.
108. Shankland SJ, Scholey JW: Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 1994;46:430-442.
109. Sharma K, Guo J, Jin Y, Ericksen M, Ziyadeh FN: Anti-TGF-β antibody attenuates renal hypertrophy and matrix expression in diabetic mice [Abstract]. J Am Soc Nephrol 1994;5:972A.
110. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994;35:F829-F842.
111. Ziyadeh FN, Wu VY, Ericksen M, Cohen MP: Glycated albumin modulates glomerular cell biology in vivo and in vitro and is recognized by cell binding proteins [Abstract]. J Am Soc Nephrol 1993;4:810A.
112. Cohen MP, Hud E, Wu VY, Ziyadeh FN: Albumin modified by Amadori glucose adducts binds to mesangial cell receptors and stimulates type IV collagen gene expression [Abstract]. J Am Soc Nephrol 1994;5:961A.
113. Wu VY, Cohen MP: Evidence for a ligand receptor system mediating the biologic effects of glycated albumin in glomerular mesangial cells. Biochem Biophys Res Commun 1995;207:521-528.
114. Fumo P, Kuncio GS, Ziyadeh FN: PKC and high glucose stimulate collagen α1(IV) transcriptional activity in a reporter mesangial cell line. J Am J Physiol 1994;267: F632-F638.
115. Cohen MP, Hud E, Wu VY, Ziyadeh FN: Albumin modified by Amadori glucose adducts activates mesangial cell type IV collagen gene transcription. Mol Cell Biochem 1995;151:61-67.
116. Like AA, Lavine RL, Poffenbarger PL, Chick WL: Studies in the diabetic mutant mouse. Am J Pathol 1972;6: 193-204.
117. Lee SM, Graham A: Early immunopathologic events in experimental diabetic nephropathy: A study in db/db mice. Exp Mol Pathol 1980;33:323-332.
118. Lee SM, Bressler R: Prevention of diabetic nephropathy by diet control in the db/db mouse. Diabetes 1981;30: 106-111.
119. Cohen MP, Hud E, Wu VY: Amelioration of diabetic nephropathy with monoclonal antibodies against glycated albumin. Kidney Int 1994;45:1673-1679.
120. Cohen MP, Sharma K, Jin Y, et al.: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: A novel treatment strategy. J Clin Invest 1995;95:2338-2345.
121. Predescu D, Simionescu M, Simionescu N, Palade G: Binding and transcytosis of glycoalbumin by the microvascular endothelium of the murine myocardium: Evidence that glycoalbumin behaves as a bifunctional ligand. J Cell Biol 1988;107:1729-1738.
122. Wu VY, Cohen MP: Identification of aortic endothelial cell binding proteins for Amadori adducts in glycated albumin. Biochem Biophys Res Commun 1993;193: 1131-1136.
123. Wu VY, Cohen MP: Receptors specific for Amadori-modified glycated albumin on murine endothelial cells. Biochem Biophys Res Commun 1994;198:734-739.
124. Krantz S, Brandt R, Gomoll B: Binding sites for short-term glycated albumin on peritoneal cells of the rat. Biochim Biophys Acta 1993;1177:15-24.
125. Ziyadeh FN: Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. Miner Electrolyte Metab 1995;21:292-302.
126. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-β as a key mediator. Diabetes 1995;44:1139-1146.
127. Williamson JR, Chang K, Frangos M, et al.: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:81-813.